![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised Phase IIb trial
|
|
|
Reported by Jules Levin
EASL 2012 April 18-22 Barcelona Spain
Stefan Zeuzem,1Thomas Berg,2Edward Gane,3Peter Ferenci,4Graham R. Foster,5MichaelW.Fried,6Christophe Hezode,7Gideon Hirschfield,8Ira Jacobson,9 Igor Nikitin,10PaulPockros,11Fred Poordad,12Oliver Lenz,13Monika Peeters,13VanithaSekar,14GoedeleDeSmedt,13Maria Beumont-Mauviel13
1JW Goethe University Hospital, Frankfurt, Germany; 2University Clinic Leipzig, Leipzig, Germany; 3Auckland Hospital Clinical Studies Unit, Auckland, New Zealand; 4Universitätsklinik für Innere Medizin III, Wien, Austria; 5Queen Marys University of London, London, UK; 6University of North Carolina at Chapel Hill, NC, USA; 7Hôpital Henri-Mondor, Université Paris-Est Créteil, France; 8Toronto Western Hospital Liver Centre, Toronto, Canada; 9Weill Cornell Medical College, New York, NY, USA; 10Russian State Medical University, Moscow, Russia; 11Scripps Clinic, La Jolla, CA, USA; 12Cedars-Sinai Medical Center, Los Angeles, CA, USA; 13 Janssen Infectious Diseases BVBA, Beerse, Belgium; 14 Janssen Research & Development LLC, Titusville, NJ, USA
![EASL1.gif](../images/041812/041912-7/EASL1.gif)
![EASL2.gif](../images/041812/041912-7/EASL2.gif)
![EASL3.gif](../images/041812/041912-7/EASL3.gif)
![EASL4.gif](../images/041812/041912-7/EASL4.gif)
![EASL5.gif](../images/041812/041912-7/EASL5.gif)
![EASL6.gif](../images/041812/041912-7/EASL6.gif)
![EASL7.gif](../images/041812/041912-7/EASL7.gif)
![EASL8.gif](../images/041812/041912-7/EASL8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|